



<b>Catalog Number:</b>	MC11105	<b>Product Type:</b>	Small Molecule
<b>Bio-Activity:</b>	HDAC inhibitor	<b>CAS #:</b>	404950-80-7
<b>Research Categories:</b>	Epigenetics, cell death, cancer	<b>Chemical Name:</b>	(E)-N-Hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide
<b>Solubility:</b>	Soluble in DMSO (up to 100 mg/ml) or in Ethanol (up to 5 mg/ml with warming).	<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>23</sub> N <sub>3</sub> O <sub>2</sub>
<b>Purity:</b>	> 98%	<b>Molecular Weight:</b>	349.44
<b>Format:</b>	Powder	<b>Ship Temp:</b>	Ambient
<b>Storage:</b>	-20°C		

### Application Notes

#### Description/Data:

A potent inhibitor of class I and II HDACs [1]. Cotreatment with panobinostat and an HSP90 inhibitor caused synergistic apoptosis in human CML-BC and AML cells [2]. A potent antimyeloma agent that overcomes drug resistance [3].

#### References:

- 1) Geng et al. (2006), Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer; *Cancer Res.*, 66 11298
- 2) George et al. (2005), Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3; *Blood*, 105 1768
- 3) Maiso et al. (2006), The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance; *Cancer Res.*, 66 5781

### FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012